Committed to the fight against Antimicrobial Resistance (AMR)

Committed to the fight against Antimicrobial Resistance (AMR)

Tackling antimicrobial resistance (AMR) requires the combined efforts of policy leaders, pharmaceutical companies, healthcare professionals and patients. As a leading global provider of anti-infective medicines and vaccines, Pfizer is at the forefront of providing solutions that protect from infectious disease. In order for this to be sustainable in the future, however, we need new business models and a predictable legislative framework in the EU to incentivise both early- and late stage R&D in new treatments and vaccines. The next EU legislature can make this happen.

 

AMR is the ability of microorganisms to resist antimicrobial treatments, especially antibiotics. In the last decades, this natural selection process has been exacerbated by human factors such as misuse of antimicrobials, and poor infection control practices1

At the same time scientific, regulatory and financial hurdles make it increasingly challenging to develop new treatments to manage resistance. Without intervention, by 2050 AMR could take 10 million lives per year globally, more than cancer4.

Tackling AMR requires the combined efforts of policy leaders, pharmaceutical companies, healthcare professionals and patients. The 2017 EU One Health Action Plan against AMR identified several key issues, and it is now time for concrete action from all public and private stakeholders.

As a global leader in anti-infectives and vaccines, Pfizer is working closely with the infectious disease community to address AMR, including through5

  • Active stewardship to help ensure patients receive the correct antibiotic only if needed and for the right duration; 
  • AMR surveillance programmes for clinicians and public health officials to assess the nature and scale of emerging resistance, both locally and nationally;


     
  • Responsible manufacturing practices that minimise the potential environmental impact related to the production of antibiotics; 
  • Diverse portfolio of medicines and vaccines to treat and help prevent serious infections across the world7.
     

EU action needed to support R&D in new solutions against AMR

The EU and its Member States have recognised the need for incentives and new business models to attract investment into R&D of new antibiotics, vaccines, alternatives, diagnostics, and stabilise the current marketplace. It is beyond time to move to concrete action.

So far, most efforts at EU level have been dedicated to “push” incentives aimed at de-risking basic research (e.g. research grants or public-private partnerships like the Innovative Medicines Initiative, IMI) via cost-sharing mechanisms. These efforts have proven valuable and should certainly continue.

In order to turn promising research into viable products, however, we urge the European Commission to put forward a legislative proposal on AMR which would include, but not be limited to, robust “pull” mechanisms at EU level, such as Transferable Exclusivity Extensions (TEE) or Market Entry Rewards (MER). Coupled with HTA and reimbursement reform at national level, these would form part of a comprehensive package of incentives that could effectively generate investments in both early- and late-stage R&D.

Key Policy Points

During the 2019-2024 EU legislature, we call on the EU and its Member States to:

  1. Maintain a high political focus on the broader issue of AMR following a “One Health” approach;
  2. Align AMR research funding, at national and EU level, with the scale of the threat;
  3. Implement comprehensive life-long vaccination programs, to help prevent infections and therefore reducing the need for antibiotic use;
  4. Design and implement, in collaboration with industry, a package of incentives at EU and national level to support research and development of additional anti-infectives and vaccines and strengthen a sustainable marketplace. 
Content image